Boston healthtech company Clairity, Inc. has raised $43 million in Series B financing to scale its flagship product, Clairity Breast, across new markets and develop additional predictive imaging tools across multiple areas of health.
According to a Thursday news release, the funding round was led by ACE Global Equity and Santé Ventures, with participation from the Breast Cancer Research Foundation and other investors.
Clairity Breast uses AI to analyze routine mammograms and predict a woman’s five-year risk of developing breast cancer, marking a shift from detection to prediction.
“For decades, we have relied on mammography to detect cancer only after it is visible. With Clairity Breast, we can now use the same images to predict who may be at risk over the next five years, supporting earlier intervention, fewer late-stage diagnoses and more lives saved,” Clairity Founder Connie Lehman said in a statement.
Building on this success, the company is also developing Clairity Heart, a similar tool designed to estimate cardiovascular risk using the same imaging data.
